Anti-CD22 Therapies - Pipeline Insight, 2024

This “Anti-CD22 Therapies - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD22 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anti-CD22 Therapies Understanding

Anti-CD22 Therapies: Overview

CD22 (Siglec 2) is a single-spanning membrane glycoprotein of 140 kDa on the surface of B cells. Plasma cells do not express the molecule. CD22 has seven extracytoplasmic Ig-like domains and belongs to the Ig superfamily. It serves as a receptor for carbohydrate determinants on a wide variety of cell surface and soluble molecules in vivo. In contrast to CD19, CD22 can act as an antagonist to B cell activation most likely by enhancing the threshold of BCR induced signals. CD22 is expressed on the surface of most B-cell leukemias and lymphomas and therefore has been explored as a target for Ab-based therapies. Research studies shows that use of chimeric antigen receptor (CAR) T-cell therapy, specific for CD22 was reported to provide high response rates for patients with B-cell acute lymphoblastic leukemia (B-ALL) who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment. The ability of CD22 to regulate both BCR and TLRs represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD22 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD22 Therapies.

Anti-CD22 Therapies Emerging Drugs Chapters

This segment of the Anti-CD22 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anti-CD22 Therapies Emerging Drugs

SM03: SinoMab Bioscience SM 03 is a recombinant human anti-CD22 monoclonal antibody. SM03 is a chimeric mAb specific to the B cell restricted antigen CD22 developed for the treatment of rheumatoid arthritis, and other immunological diseases such as systemic lupus erythematosus and Sjogren’s syndrome. The drug is currently in Phase III clinical trial for rheumatoid arthritis inChina.

AUTO3: Autolus AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in diffuse large B cell lymphoma in the ALEXANDER clinicaltrial.

Anti-CD22 Therapies: Therapeutic Assessment

This segment of the report provides insights about the different Anti-CD22 Therapies drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Anti-CD22 Therapies

There are approx. 10+ key companies which are developing the Anti-CD22 Therapies. The companies which have their Anti-CD22 Therapies drug candidates in the most advanced stage, i.e. Phase III include, SinoMab Bioscience.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Anti-CD22 Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anti-CD22 Therapies: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD22 Therapies therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD22 Therapies drugs.

Anti-CD22 Therapies Report Insights

• Anti-CD22 Therapies Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anti-CD22 Therapies Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Anti-CD22 Therapies drugs?
• How many Anti-CD22 Therapies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD22 Therapies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anti-CD22 Therapies therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anti-CD22 Therapies and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• SinoMab Bioscience
• Autolus
• Shanghai Unicar-Therapy Bio-medicine Technology
• Cellectis
• Allife Medical Science and Technology

Key Products

• SM03
• AUTO3
• Anti CD22 chimeric antigen receptor T cell therapy
• UCART 22
• Anti-CD22 CAR NK Cells

This product will be delivered within 2 business days.